Company Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.
Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis.
The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016.
DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Dietrich Pauls |
Contact Details
Address: 301 Carlson Parkway, Suite 210 Minneapolis, Minnesota 55305 United States | |
| Phone | 763 496 5454 |
| Website | diamedica.com |
Stock Details
| Ticker Symbol | DMAC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001401040 |
| CUSIP Number | 25253X207 |
| ISIN Number | CA25253X2077 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dietrich John Pauls MBA | President, Chief Executive Officer and Director |
| Scott Kellen CPA | Chief Financial Officer and Corporate Secretary |
| Dr. Ambarish Shah Ph.D. | Chief Technology Officer |
| Dominic R. Cundari | Chief Commercial Officer |
| David J. Wambeke | Chief Business Officer |
| Dr. Alex Aimetti Ph.D. | Chief Development Officer |
| Dr. Julie Krop M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | 8-K | Current Report |
| Aug 12, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Aug 8, 2025 | EFFECT | Notice of Effectiveness |
| Aug 6, 2025 | 8-K | Current Report |
| Aug 1, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 30, 2025 | SCHEDULE 13G/A | Filing |
| Jul 30, 2025 | SCHEDULE 13G/A | Filing |
| Jul 25, 2025 | D | Notice of Exempt Offering of Securities |